The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.a

Respiratory tract infection incl. pneumonia

Publications

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, IMPACT Investigators

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

The New England journal of medicine. 2018;378(18):1671-1680

Janson C, Stratelis G, Miller-Larsson A, Harrison TW, Larsson K

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.

International journal of chronic obstructive pulmonary disease. 2017;12:3055-3064

Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM

Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.

Annals of the American Thoracic Society. 2015;12(1):27-34

Mattishent K, Thavarajah M, Blanco P, Gilbert D, Wilson AM, Loke YK

Meta-review: adverse effects of inhaled corticosteroids relevant to older patients.

Drugs. 2014;74(5):539-47

Suissa S, Patenaude V, Lapi F, Ernst P

Inhaled corticosteroids in COPD and the risk of serious pneumonia.

Thorax. 2013;68(11):1029-36